The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy-Reference-Cited by-同舟云学术

The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy

Published:2014-07-11 Issue:10 Volume:86 Page:1648-1655
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:J. Med. Virol.

Author:

Di Biagio Antonio¹,Rusconi Stefano²,Marzocchetti Angela³,Signori Alessio⁴,Schiavetti Irene⁴,Bruzzone Bianca⁵,Monno Laura⁶,Punzi Grazia⁶,Colao Maria Grazia⁷,Penco Giovanni⁸,Zazzi Maurizio⁹,De Luca Andrea³¹⁰,

Affiliation:

1. Clinic of Infectious Diseases; IRCCS San Martino-IST, National Institute of Cancer; Genoa Italy

2. Clinic of Infectious Diseases; DIBIC “Luigi Sacco”, University of Milan; Milan Italy

3. Institute of Clinical Infectious Diseases; Catholic University of Sacred Heart; Rome Italy

4. Biostatistics Unit; Department of Health Sciences; University of Genoa; Genoa Italy

5. Hygiene Unit; IRCCS San Martino-IST; National Institute of Cancer; Genoa Italy

6. Clinic of Infectious Diseases; University of Bari; Bari Italy

7. Institute of Virology; AOU Careggi; Firenze Italy

8. Department of Infectious Diseases; EO Galliera; Genoa Italy

9. Department of Medical Biotechnologies; University of Siena; Siena Italy

10. University Division of Infectious Diseases; University Hospital of Siena; Siena Italy

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jmv.24017/fullpdf

Reference27 articles.

1. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy;Anastos;Ann Intern Med,2004

2. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies;Antiretroviral Therapy Cohort Collaboration;Lancet,2008

3. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus infected adults;Barbour;J Virol,2002

4. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naıve, HIV-1-infected patients: Pooled results from the phase 3 double-blind, randomized ECHO and THRIVE trials;Cohen;J Acquir Immune Defic Syndr,2012

5. Sex-based outcomes of darunavir-ritonavir therapy: A single-group trial;Currier;Ann Intern Med,2010

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD4+ T lymphocyte recovery in the modern antiretroviral therapy era: Toward a new threshold for defining immunological non-responders;Frontiers in Virology;2023-01-10

2. BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022;HIV Medicine;2022-12

3. Impact of pre-antiretroviral treatment HIV-RNA on time to successful virological suppression and subsequent virological failure – two nationwide, population-based cohort studies;AIDS;2022-11-10

4. Early versus delayed antiretroviral therapy based on genotypic resistance test: Results from a large retrospective cohort study;Journal of Medical Virology;2022-04-09

5. Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV;PLOS ONE;2022-02-03